Pharmacy Chemistry Electrolytic Manganese Dioxide
Short Product Description
Pharmacy chemistry electrolytic manganese dioxide (EMD) is a high-purity ≥99.0% MnO₂ material produced by controlled electrolysis for pharmaceutical and fine chemical synthesis. It is suitable as an oxidizing agent and catalyst intermediate where low heavy metal content and stable reactivity are required. This grade is manufactured under strict impurity control to meet pharmacy chemistry standards.
Technical Specifications
| Parameter | Typical Range | Test Method |
|---|---|---|
| MnO₂ Content | ≥ 99.0% | Redox titration |
| Mn (Total) | ≥ 63.0% | ICP-OES |
| Fe | ≤ 0.01% | ICP |
| Pb | ≤ 0.002% | ICP |
| Cu | ≤ 0.002% | ICP |
| Moisture | ≤ 1.0% | 105°C drying |
| pH (10% slurry) | 4.0 – 6.5 | pH meter |
| Surface Area | 30 – 60 m²/g | BET |
| Particle Size (D50) | 5 – 20 μm | Laser diffraction |
Key Features
High chemical purity suitable for pharmacy chemistry electrolytic manganese dioxide applications
Low heavy metal impurities to meet pharmaceutical synthesis requirements
Controlled particle size distribution for consistent reaction kinetics
Stable oxidation potential and reproducible batch performance
Low residual sulfate and chloride content
Available in fine powder or customized particle grades
Applications
Pharmaceutical intermediate synthesis – Used as a selective oxidizing agent in API and intermediate production.
Fine chemical oxidation reactions – Suitable for alcohol-to-aldehyde or ketone conversions.
Laboratory-scale and pilot-scale research – Consistent activity for process validation.
Specialty organic synthesis – Reliable performance in controlled redox reactions.
Pharmacy chemistry electrolytic manganese dioxide for regulated manufacturing environments requiring impurity control.
Key Challenges in MnO₂ Oxidation and Our Solution
In pharmaceutical and fine chemical synthesis, the quality of manganese dioxide directly affects oxidation selectivity, reaction efficiency, and product purity. Many industrial MnO₂ materials contain only 90–94% active MnO₂, which can lead to inconsistent reaction performance and unwanted impurities.
Our electrolytic manganese dioxide is designed to overcome these limitations.
Lower purity MnO₂ can cause side reactions
Many conventional manganese dioxide products contain only 90–94% MnO₂, meaning inactive minerals and trace impurities may interfere with oxidation reactions.
Our electrolytic manganese dioxide offers ≥99% MnO₂ purity, significantly reducing impurity interference and improving reaction reliability in pharmaceutical synthesis.
Low activity can slow oxidation reactions
The oxidation efficiency of MnO₂ strongly depends on its surface activity and crystal structure.
Our controlled electrolytic production process generates highly active MnO₂ with optimized surface area, providing faster and more efficient oxidation in allylic and benzylic alcohol reactions.
Inconsistent material quality between batches
Variations in particle size and crystal phase can lead to unstable reaction kinetics and inconsistent yields.
Our MnO₂ is produced under controlled electrochemical conditions with stable γ-MnO₂ crystal structure, ensuring reproducible performance for laboratory and fine chemical applications.
Difficult filtration after reaction
Poor particle control can cause slow filtration and operational inefficiencies during work-up.
Our MnO₂ powder is manufactured with controlled particle size distribution, improving solid-liquid separation after oxidation reactions.
Packaging & Supply
25 kg fiber drum with double PE inner liner
500 kg or 1000 kg bulk bags available
Palletized and export-grade packaging
Suitable for sea and air freight shipment
Customization & Technical Support
Adjustable particle size distribution and surface area
Impurity levels optimized based on target pharmacopeia standards
Batch COA and traceability documentation provided
Technical support for reaction optimization and scale-up assistance
For detailed specifications or regulatory documentation, technical data sheets are available upon request.
FAQ
What is electrolytic manganese dioxide used for in pharmaceutical chemistry?
Electrolytic manganese dioxide is widely used as a selective oxidizing agent in pharmaceutical and fine chemical synthesis. It helps convert allylic and benzylic alcohols into aldehydes or ketones while maintaining good reaction selectivity.
Why is high purity MnO2 important for chemical synthesis?
High purity manganese dioxide ensures more stable reaction conditions and better product quality. Low impurity levels help avoid unwanted side reactions during pharmaceutical intermediate production.
How does electrolytic MnO2 differ from chemical MnO2?
Electrolytic manganese dioxide generally has higher purity and more consistent crystal structure than chemically produced MnO2. This makes it more suitable for laboratory research and pharmaceutical synthesis.
What types of reactions commonly use MnO2?
MnO2 is often used in oxidation reactions such as converting allylic alcohols into aldehydes and secondary alcohols into ketones. It is also used in fragrance intermediates and fine chemical production.
What factors influence MnO2 performance in organic reactions?
The performance of manganese dioxide depends on purity, surface area, particle size, and crystal phase. These properties affect oxidation efficiency and reaction selectivity.
Can MnO2 specifications be customized for laboratory applications?
Yes. Manufacturers can adjust particle size, activity level, and impurity limits according to specific laboratory or industrial synthesis requirements.
You can also check out specifications for these applications:
High-Purity Manganese Dioxide for Pharmaceutical Synthesis
Manganese Dioxide for Dehydrogenation Reactions
Pharmacy Chemistry Electrolytic Manganese Dioxide (EMD)
High-purity Pharmacy Chemistry Electrolytic Manganese Dioxide (EMD ≥ 99.0%) produced through controlled electrolysis for the most demanding fine chemical synthesis. This premium oxidizing agent features ultra-low heavy metal content (Fe ≤ 0.01%, Pb/Cu ≤ 0.002%), a high surface area (30–60 m²/g), and a controlled particle size (5–20 μm), ensuring stable reactivity and high selectivity for API and pharmaceutical intermediate production.
Product SKU: EMD-PHARMA-990
Product Brand: BTL New Material
Product In-Stock: InStock
5